Tag: ASX: ALA
Arovella’s ALA-101 inches toward clinic following key manufacturing achievement
Arovella Therapeutics Ltd, the biotechnology company specialising in iNKT cell therapy, announced that the Good Manufacturing Practice (GMP)-grade lentiviral vector for its lead product, ALA-101, has completed successful manufacturing and quality release testing.
Featured Article
Navigating energy price volatility with predictive intelligence
Energy price volatility has become a structural feature of modern electricity markets rather than a temporary disruption. For energy-intensive manufacturers and large commercial operators, fluctuating wholesale prices are reshaping how energy costs are managed, making reactive approaches increasingly inadequate.
